Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT)

IMPORTANCE: The cardiovascular and renal outcomes of angiotensin-II receptor blocker (ARB) and angiotensin-converting enzyme inhibitor (ACEI) treatment are well-known; however, few studies have evaluated initiation of these agents and cognitive impairment. OBJECTIVE: To emulate a target trial to eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Jordana B., Marcum, Zachary A., Zhang, Chong, Derington, Catherine G., Greene, Tom H., Ghazi, Lama, Herrick, Jennifer S., King, Jordan B., Cheung, Alfred K., Bryan, Nick, Supiano, Mark A., Sonnen, Joshua A., Weintraub, William S., Scharfstein, Daniel, Williamson, Jeff, Pajewski, Nicholas M., Bress, Adam P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284332/
https://www.ncbi.nlm.nih.gov/pubmed/35834254
http://dx.doi.org/10.1001/jamanetworkopen.2022.20680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284332/
https://www.ncbi.nlm.nih.gov/pubmed/35834254
http://dx.doi.org/10.1001/jamanetworkopen.2022.20680

Ejemplares similares